文献速递肿瘤 PET/CT核素与放射性配体治疗

C-X-C趋化因子受体4靶向分子影像与治疗的观察者间一致性率

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy.
PubMed 文献 · Clin Nucl Med · 2023-03-22

研究评估了CXCR4靶向PET/CT的观察者间一致性,4名独立观察者回顾性分析50例实体瘤患者的[68Ga]pentixafor PET/CT。视觉评估中,总体扫描印象一致性为fair(ICC 0.58),器官和淋巴结转移数目及CXCR4密度为good至excellent;定量分析中淋巴结和器官病灶摄取一致性excellent(ICC≥0.92),参考器官摄取一致性fair(ICC≥0.54),判定CXCR4-RLT合格患者的一致性excellent(ICC 0.91)。

要点

  • 50例实体瘤患者[68Ga]pentixafor PET/CT由4名观察者独立评估。
  • 总体扫描印象一致性fair(ICC 0.58;95%CI 0.45-0.71)。
  • 判定CXCR4-RLT合格患者一致性excellent(ICC 0.91;95%CI 0.85-0.95)。

核心结论

  • 在CXCR4靶向PET/CT扫描的患者中,分子影像和治療参数均观察到fair至excellent的观察者间一致性,作者认为这支持[68Ga]pentixafor在临床中更广泛地应用。

研究设计与样本

  • 4名独立观察者回顾性分析50例各种实体瘤患者的CXCR4靶向[68Ga]pentixafor PET/CT。
  • 视觉评估项目包括总体扫描印象、器官和淋巴结转移数目及受累器官和淋巴结区域数。
  • 定量分析要求每位观察者最多选择3个靶病灶,定义为每个器官隔室中尺寸最大和/或摄取最强者,并量化未受累肝实质和血池等参考组织。
  • 所有观察者判定患者是否适合CXCR4靶向放射性配体治疗(RLT)。
  • 一致性采用组内相关系数(ICC)检验,按Cicchetti定义解读:0.4-0.59为fair,0.6-0.74为good,0.75-1为excellent。

主要发现

  • 视觉评估中,总体扫描印象一致性fair(ICC 0.58;95%CI 0.45-0.71)。
  • 器官和淋巴结受累一致性fair(ICC≥0.4),而CXCR4密度及淋巴结和器官转移数目一致性good(ICC≥0.65)。
  • 受累器官数和受累淋巴结区域数一致性excellent(ICC≥0.76)。
  • 淋巴结和器官病灶定量分析一致性excellent(ICC≥0.92),参考器官定量摄取一致性fair(ICC≥0.54)。
  • 判定患者适合CXCR4-RLT的一致性excellent(ICC 0.91;95%CI 0.85-0.95)。

关键数值与推荐

  • 总体扫描印象ICC 0.58(95%CI 0.45-0.71),按Cicchetti标准为fair。
  • CXCR4密度及淋巴结和器官转移数目ICC≥0.65,为good。
  • 受累器官数和受累淋巴结区域数ICC≥0.76,为excellent。
  • 淋巴结和器官病灶定量摄取ICC≥0.92,为excellent;参考器官定量摄取ICC≥0.54,为fair。
  • CXCR4-RLT合格患者判定ICC 0.91(95%CI 0.85-0.95),为excellent。

临床怎么用

  • 原文结论认为观察到的fair至excellent一致性支持[68Ga]pentixafor在临床中更广泛地应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate the interobserver agreement rates in patients scanned with C-X-C motif chemokine receptor 4 (CXCR4)-directed PET/CT, including the rate of patients eligible for CXCR4-targeted radioligand therapy (RLT) based on scan results. METHODS: Four independent observers reviewed 50 CXCR4-targeted [ 68 Ga]pentixafor PET/CT of patients with various solid cancers. On a visual level, the following items were assessed by each reader: overall scan impression, number of organ and lymph node (LN) metastases and number of affected organs and LN regions. For a quantitative investigation, readers had to choose a maximum of 3 target lesions, defined as largest in size and/or most intense uptake per organ compartment. Reference tissues were also quantified, including unaffected hepatic parenchyma and blood pool. Last, all observers had to decide whether patients were eligible for CXCR4-targeted RLT. Concordance rates were tested using intraclass correlation coefficients (ICCs). For interpretation, we applied the definition of Cicchetti (with 0.4-0.59 indicating fair; 0.6-0.74, good; 0.75-1, excellent agreement). RESULTS: On a visual level, fair agreement was achieved for an overall scan impression (ICC, 0.58; 95% confidence interval, 0.45-0.71). Organ and LN involvement (ICC, ≥0.4) demonstrated fair, whereas CXCR4 density and number of LN and organ metastases showed good agreement rates (ICC, ≥0.65). Number of affected organs and affected LN areas, however, showed excellent concordance (ICC, ≥0.76). Quantification in LN and organ lesions also provided excellent agreement rates (ICC, ≥0.92), whereas quantified uptake in reference organs provided fair concordance (ICC, ≥0.54). Again, excellent agreement rates were observed when deciding on patients eligible for CXCR4-RLT (ICC, 0.91; 95% confidence interval, 0.85-0.95). CONCLUSIONS: In patients scanned with CXCR4-targeted PET/CT, we observed fair to excellent agreement rates for both molecular imaging and therapy parameters, thereby favoring a more widespread adoption of [ 68 Ga]pentixafor in the clinic.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Kosmala A, Serfling SE, et al. Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy. Clin Nucl Med. 2023. PMID: 36947793. doi:10.1097/RLU.0000000000004629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。